These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34975266)

  • 21. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.
    Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
    bioRxiv; 2021 Nov; ():. PubMed ID: 34790980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Genomics and epidemiology of SARS-CoV-2 lineage].
    Sukegawa S; Takeuchi H
    Uirusu; 2021; 71(1):19-32. PubMed ID: 35526991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.
    Wu K; Werner AP; Moliva JI; Koch M; Choi A; Stewart-Jones GBE; Bennett H; Boyoglu-Barnum S; Shi W; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
    bioRxiv; 2021 Jan; ():. PubMed ID: 33501442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional Antibodies Against SARS-CoV-2 Receptor Binding Domain Variants with Mutations N501Y or E484K in Human Milk from COVID-19-Vaccinated, -Recovered, and -Unvaccinated Women.
    Demers-Mathieu V; Hakansson AP; Hall S; Lavangnananda S; Fels S; Medo E
    Breastfeed Med; 2022 Feb; 17(2):163-172. PubMed ID: 34809492
    [No Abstract]   [Full Text] [Related]  

  • 25. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity.
    Motozono C; Toyoda M; Zahradnik J; Saito A; Nasser H; Tan TS; Ngare I; Kimura I; Uriu K; Kosugi Y; Yue Y; Shimizu R; Ito J; Torii S; Yonekawa A; Shimono N; Nagasaki Y; Minami R; Toya T; Sekiya N; Fukuhara T; Matsuura Y; Schreiber G; ; Ikeda T; Nakagawa S; Ueno T; Sato K
    Cell Host Microbe; 2021 Jul; 29(7):1124-1136.e11. PubMed ID: 34171266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal.
    Wang HX; Zhang L; Liang ZT; Nie JH; Wu JJ; Li QQ; Ding RX; Zhang Y; Chen GQ; Wang YC; Wang HG; Huang WJ
    Arch Virol; 2022 Feb; 167(2):459-470. PubMed ID: 35083576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-range enhancement of N501Y-endowed mouse infectivity of SARS-CoV-2 by the non-RBD mutations of Ins215KLRS and H655Y.
    Zhu Y; Zhou W; Niu Z; Sun J; Zhang Z; Li Q; Zheng Y; Wang C; Gao L; Sun Q
    Biol Direct; 2022 Jun; 17(1):14. PubMed ID: 35658928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera.
    Li G; Zhou Z; Du P; Yu M; Li N; Xiong X; Huang H; Liu Z; Dai Q; Zhu J; Guo C; Wu S; Baptista-Hon DT; Miao M; Ming LW; Wu Y; Zeng F; Zhang CL; Zhang ED; Song H; Liu J; Lau JY; Xiang AP; Zhang K
    Precis Clin Med; 2021 Sep; 4(3):149-154. PubMed ID: 35693215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The challenge of screening SARS-CoV-2 variants of concern with RT-qPCR: One variant can hide another.
    Blairon L; Cupaiolo R; Piteüs S; Beukinga I; Tré-Hardy M
    J Virol Methods; 2021 Nov; 297():114248. PubMed ID: 34332998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity.
    Tang H; Gao L; Wu Z; Meng F; Zhao X; Shao Y; Shi X; Qiao S; An J; Du X; Qin FX
    Front Cell Infect Microbiol; 2021; 11():720357. PubMed ID: 34722330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
    Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menacherry V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
    bioRxiv; 2022 Mar; ():. PubMed ID: 33972947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants.
    Wang Q; Ye SB; Zhou ZJ; Li JY; Lv JZ; Hu B; Yuan S; Qiu Y; Ge XY
    J Med Virol; 2023 Jan; 95(1):e28116. PubMed ID: 36056469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
    Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
    Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants.
    Gellenoncourt S; Saunders N; Robinot R; Auguste L; Rajah MM; Kervevan J; Jeger-Madiot R; Staropoli I; Planchais C; Mouquet H; Buchrieser J; Schwartz O; Chakrabarti LA
    J Virol; 2022 Oct; 96(19):e0130122. PubMed ID: 36121299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the Interaction between E484K and N501Y Substitutions of SARS-CoV-2 in Shaping the Transmission Advantage of COVID-19 in Brazil: A Modeling Study.
    Zhao S; Ran J; Han L
    Am J Trop Med Hyg; 2021 Sep; 105(5):1247-1254. PubMed ID: 34583340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The emerging SARS-CoV-2 variants of concern.
    Sanyaolu A; Okorie C; Marinkovic A; Haider N; Abbasi AF; Jaferi U; Prakash S; Balendra V
    Ther Adv Infect Dis; 2021; 8():20499361211024372. PubMed ID: 34211709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility.
    Gan HH; Twaddle A; Marchand B; Gunsalus KC
    J Mol Biol; 2021 Jul; 433(15):167051. PubMed ID: 33992693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
    Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.